All In Biotech

Drug Trial Radar · NCT05185622

A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Mar 21, 2022

Primary completion

Jul 16, 2024

Study completion Jul 16, 2024

Sponsor

Lead sponsor
Santhera PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning vamorolone over a treatment period of 12 weeks in steroid-naïve boys ages 2 to \<4 years, and glucocorticoid-treated and currently untreated boys ages 7 to \<18 years with DMD.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • VamoroloneDrug

    Oral administration of vamorolone for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
  2. Number of Participants With Drug Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
  3. Number of Participants With Severe Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
  4. Number of Participants With Serious Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed (SAEs through 30 days after final dose of study drug)
  5. Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) Leading to Study Treatment DiscontinuationTime frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
  6. Change in Height (Absolute) From Baseline to Week 12Time frame: Baseline, 12 weeks
  7. Change in Height (Percentile) From Baseline to Week 12Time frame: Baseline, 12 weeks
  8. Change in Height (Z-score) From Baseline to Week 12Time frame: Baseline, 12 weeks
  9. Change in Weight (Absolute) From Baseline to Week 12Time frame: Baseline, 12 weeks
  10. Change in Weight (Percentile) From Baseline to Week 12Time frame: Baseline, 12 weeks
  11. Change in Weight (Z-score) From Baseline to Week 12Time frame: Baseline, 12 weeks
  12. Change in Body Mass Index (BMI) (Absolute) From Baseline to Week 12Time frame: Baseline, Week 12
  13. Change in Body Mass Index (BMI) (Percentile) From Baseline to Week 12Time frame: Baseline, Week 12
  14. Change in Body Mass Index (BMI) (Z-score) From Baseline to Week 12Time frame: Baseline, Week 12
  15. Change in Diastolic Blood PressureTime frame: Day 1, Week 2, Week 6, Week 12, Week 16
  16. Change in Systolic Blood PressureTime frame: Day 1, Week 2, Week 6, Week 12, Week 16
  17. Number of Participants With Treatment Emergent Cushingoid FeaturesTime frame: Baseline through Week 16
  18. Number of Participants With Clinically Significant Treatment-emergent Abnormal Clinical Laboratory Test ResultTime frame: Day 1, Week 6, Week 12, Week 16
  19. Categorical Analysis of QTcF at Week 12Time frame: Baseline, Week 12
  20. Number of Eyes With CataractTime frame: Baseline - Week 12
  21. Number of Eyes With GlaucomaTime frame: Baseline - Week 12

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Montreal Childrens Hospital

    Montreal, Canada

  • Alberta's Children Hospital

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.